RBC Capital Upgrades Lakefront Biotherapeutics to Outperform, Raises Price Target to $45

RBC Capital analyst Brian Abrahams has upgraded Lakefront Biotherapeutics (NASDAQ: LKFT) from Sector Perform to Outperform. The price target for the stock has been raised significantly from $26 to $45.